转移性前列腺癌骨转移患者早期[18F]氟化钠正电子发射断层扫描/计算机断层扫描治疗反应的定量评估
56例转移性去势抵抗性前列腺癌(mCRPC)骨转移患者在接受3周期化疗(n=16)或雄激素受体通路抑制剂(n=40)前后行[18F]氟化钠(NaF)PET/CT,采用定量全骨成像分析。治疗中期功能负荷(SUVtotal)是最强的单变量无进展生存(PFS)预测因子(HR 1.97,95%CI 1.44–2.71,P<.001)。基于功能负荷变化的患者分类与PFS的相关性强于病灶数量变化,多种全局影像指标优于基线临床标志物。
要点
- 治疗中期SUVtotal是mCRPC骨转移患者PFS最强的单变量预测因子(HR 1.97,95%CI 1.44–2.71,P<.001)。
- 基于功能负荷变化的分类与PFS的相关性强于病灶数量变化。
- SUVtotal和SUVmean等全局影像指标在预测结局上优于基线临床标志物。
核心结论
- 定量全骨成像可在NaF PET/CT上实现全面疾病定量,与临床结局强相关;激素治疗或化疗3周期后评估的总功能负荷可预测mCRPC男性的PFS。
研究设计与样本
- 研究纳入56例伴骨转移的转移性去势抵抗性前列腺癌(mCRPC)患者,在基线和3周期化疗(n=16)或雄激素受体通路抑制剂(n=40)后行NaF PET/CT,采用定量全骨成像分析。
主要发现
- 治疗中期功能负荷(SUVtotal)是最强的单变量PFS预测因子(HR 1.97,95%CI 1.44–2.71,P<.001)。
- 基于功能负荷变化的患者分类与PFS的相关性强于病灶数量变化。
- SUVtotal和SUVmean等多种全局影像指标在预测结局上优于基线临床标志物。
- 不同治疗队列间未发现影像缓解或PFS相关因素的差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose [18F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastases. This study assesses changes in early NaF PET/CT response measures in metastatic prostate cancer for correlation to clinical outcomes. Patients and Methods Fifty-six patients with metastatic castration-resistant prostate cancer (mCRPC) with osseous metastases had NaF PET/CT scans performed at baseline and after three cycles of chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 40). A novel technology, Quantitative Total Bone Imaging, was used for analysis. Global imaging metrics, including maximum standardized uptake value (SUVmax) and total functional burden (SUVtotal), were extracted from composite lesion-level statistics for each patient and tracked throughout treatment. Progression-free survival (PFS) was calculated as a composite end point of progressive events using conventional imaging and/or physician discretion of clinical benefit; NaF imaging was not used for clinical evaluation. Cox proportional hazards regression analyses were conducted between imaging metrics and PFS. Results Functional burden (SUVtotal) assessed midtreatment was the strongest univariable PFS predictor (hazard ratio, 1.97; 95% CI, 1.44 to 2.71; P < .001). Classification of patients based on changes in functional burden showed stronger correlation to PFS than did the change in number of lesions. Various global imaging metrics outperformed baseline clinical markers in predicting outcome, including SUVtotal and SUVmean. No differences in imaging response or PFS correlates were found for different treatment cohorts. Conclusion Quantitative total bone imaging enables comprehensive disease quantification on NaF PET/CT imaging, showing strong correlation to clinical outcomes. Total functional burden assessed after three cycles of hormonal therapy or chemotherapy was predictive of PFS for men with mCRPC. This supports ongoing development of NaF PET/CT-based imaging biomarkers in mCRPC to bone.
引用
- Harmon SA, Perk T, Lin C, et al. Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. J Clin Oncol. 2017. PMID: 28654366. doi:10.1200/JCO.2017.72.2348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。